ATRAAtara Biotherapeutics Inc
ATRA
Atara Biotherapeutics Inc3,659
Mkt Cap
$37.54MVolume
51,349.0052W High
$19.1552W Low
$3.92PE Ratio
1.57ATRA Fundamentals
Price
$4.59Prev Close
$4.71Open
$4.7150D MA
$5.06Beta
2.22Avg. Volume
136,424.98EPS (Annual)
$2.57P/B
-0.87Rev/Employee
$8.63M$274.38
Poll
Earnings Recap
Atara Biotherapeutics anticipates its existing capital resources of $8.5M as of December 31, 2025, will be insufficient to fund planned operations for at least the next twelve months.
Bullish
Atara Biotherapeutics reported net income of $32.7 million, successfully resolved prior FDA GMP compliance issues for tab-cel, and secured substantial milestone payments from its expanded Pierre Fabre commercialization agreement.
Bearish
Atara Biotherapeutics faces going concern doubts due to insufficient capital, a second FDA Complete Response Letter for tab-cel, and high dependence on Pierre Fabre for commercialization.